首页> 外文期刊>British journal of ophthalmology >A randomised trial of povidone-iodine to reduce visual impairment from corneal ulcers in rural Nepal.
【24h】

A randomised trial of povidone-iodine to reduce visual impairment from corneal ulcers in rural Nepal.

机译:聚维酮碘降低尼泊尔农村角膜溃疡视力损害的随机试验。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To assess whether povidone-iodine provided any benefit over and above a standard regimen of antibiotic therapy for the treatment of corneal ulcers. METHODS: All patients diagnosed with corneal ulcers presenting for care at a primary eye care clinic in rural Nepal were randomised to a standard protocol of antibiotic therapy versus standard therapy plus 2.5% povidone-iodine every 2 hours for 2 weeks. The main outcomes were corrected visual acuity and presence, size, and position of corneal scarring in the affected eye at 2-4 months following treatment initiation. RESULTS: 358 patients were randomised and 81% were examined at follow up. The two groups were comparable before treatment. At follow up, 3.9% in the standard therapy and 6.9% in the povidone-iodine group had corrected visual acuity worse than 20/400 (relative risk (RR) 1.77, 95% confidence interval (CI) 0.62 to 5.03). 9.4% in the standard therapy and 13.1% in the povidone-iodine group had corrected visual acuity worse than 20/60 (RR 1.39, 95% CI 0.71 to 2.77), and 17.0% and 18.8% had scars in the visual axis in each of these groups, respectively (RR 1.11, 95% CI 0.67 to 1.82). CONCLUSIONS: A small proportion of patients with corneal ulceration treated in this setting had poor visual outcomes. The addition of povidone-iodine to standard antibiotic therapy did not improve visual outcomes, although this design was unable to assess whether povidone-iodine on its own would have resulted in comparable visual outcomes to that of standard therapy.
机译:目的:评估聚维酮碘在治疗角膜溃疡的标准抗生素治疗方案之外是否提供任何益处。方法:将所有在尼泊尔农村地区初诊眼科门诊就诊为角膜溃疡的患者随机分为标准方案的抗生素治疗与标准治疗加标准疗法加2.5%聚维酮碘治疗,持续2周。在治疗开始后2-4个月,主要结局是矫正视敏度以及患眼中角膜瘢痕的存在,大小和位置。结果:358例患者被随机分组​​,随访时检查了81%。两组在治疗前相当。随访时,标准疗法的矫正视力低于20/400(标准风险为3.9%,聚维酮碘治疗组为6.9%)(相对风险(RR)1.77,95%置信区间(CI)0.62至5.03)。标准疗法的9.4%和聚维酮碘疗法组的13.1%的矫正视力均低于20/60(RR 1.39,95%CI 0.71至2.77),分别有17.0%和18.8%的视轴有疤痕这些组分别为(RR 1.11,95%CI 0.67至1.82)。结论:在这种情况下接受治疗的角膜溃疡患者中有一小部分的视觉效果较差。在标准抗生素治疗中添加聚维酮碘不能改善视觉效果,尽管这种设计无法评估聚维酮碘本身是否会产生与标准治疗相当的视觉效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号